Brief: Lantheus Announces FDA Approval Of Pylarify TruVu™ (piflufolastat F 18) Injection
06/03/2026 21:04
March 6 (Reuters) - Lantheus Holdings Inc LNTH.O: LANTHEUS ANNOUNCES FDA APPROVAL OF PYLARIFY TRUVU™ (PIFLUFOLASTAT F 18) INJECTION LANTHEUS HOLDINGS INC - PYLARIFY TRUVU EXPECTED TO LAUNCH IN Q4 2026 WITH PHASED ROLLOUT Source text: ID:nGNXqtn6x Further company coverage: LNTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantheus Holdings
See all newsBrief: Lantheus Receives Complete Response Letter From FDA For Lnth-2501 (Ga 68 Edotreotide)
US FDA declines Lantheus’ tumor imaging kit over third-party manufacturing issues (updated)
US FDA declines to approve Lantheus’ tumor imaging kit
$7 billion could be a 'light' price tag for Lantheus, Truist analysts say
Lantheus falls after report it is considering potential $7 billion sale